GlassScriptPhysician profile
Amy W Castilano
NPI 1164782751
$15,999.93
in general payments reported to CMS, 2019-2025
27 companies · $2,527 in 2025
The $2,527 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,778 · 2020: $2,024 · 2021: $1,491 · 2022: $1,169 · 2023: $1,280 · 2024: $5,731 · 2025: $2,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,644 · Consulting Fee: $3,860 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,644.06 |
| Consulting Fee | $3,860.00 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,760.05 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,224.84 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $2,086.99 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,530.39 | 2019-2025 | |
| Optinose US, INC. | $1,304.92 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $610.06 | 2019-2025 | Dupixent |
| Pfizer INC. | $318.33 | 2019-2022 | |
| Grifols USA, LLC | $294.81 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Teva Pharmaceuticals USA, INC. | $282.41 | 2019-2022 | |
| Csl Behring | $269.32 | 2019-2024 | Hizentra, Haegarda |
| Kaleo, INC. | $256.83 | 2019-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $184.01 | 2025 | Neffy |
| Genentech USA, INC. | $170.12 | 2021-2025 | Xolair |
| Alk-Abello, INC | $149.20 | 2019-2020 | |
| Amgen INC. | $109.69 | 2025 | Tezspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $89.70 | 2023-2025 | Ryaltris |
| Mylan Specialty L.P. | $66.75 | 2019-2020 | |
| Covis Pharma Gmbh | $53.44 | 2020-2021 | |
| Stryker Corporation | $48.55 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.38 | 2022-2024 | Glassia |
| Merck Sharp & Dohme LLC | $29.46 | 2023 | |
| Paratek Pharmaceuticals, INC. | $29.21 | 2025 | Xhance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.86 | 2021 | |
| Uswm, LLC | $17.86 | 2021 | |
| Lilly USA, LLC | $17.21 | 2024 | Ebglyss |
| Eyevance Pharmaceuticals LLC | $15.09 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Castilano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.